SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission
ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients and clinically meaningful mortality events for evaluating interleukin-6 ("IL-6") as a biomarker associated with 28-day mortality risk in patients with sepsis and septic shock.
The current preliminary SYMON-II analysis includes 777 evaluable patients, consisting of 637 28-day survivors and 140 28-day non-survivors, representing an overall 28-day mortality rate of approximately 18%. The study population included patients across a broad spectrum of illness severity, ethnicity and geographical distribution with 39.5% meeting Sepsis-3 criteria for septic shock.
The clinical characteristics demonstrate substantial disease burden and severity. 84.0% of patients had bacterial infection reported, 32.4% had a positive blood culture, and infection was considered highly likely or likely in 86.5% of the study population.
Patients who did not survive through 28 days demonstrated greater baseline illness severity. Septic shock was present in 56.4% of non-survivors compared with 35.8% of survivors.